Regeneron Pharmaceuticals, Inc. Drug to Lower Gout Flares Meets Goal in Study

Sept 3 (Reuters) - Regeneron Pharmaceuticals Inc said a mid-stage study of its experimental treatment for gout, Arcalyst, met the main goal and reduced the incidence of gout flares by 81 percent.